Anthracyclines in non-small cell lung cancer

The literature concerning the use of anthracyclines in the treatment of non-small cell lung cancer (NSCLC) is reviewed here. Overall, the activity of doxorubicin (DOXO) is unsatisfactory, whereas, the analogous epidoxorubicin (EPI) yields a 30% response rate (RR) when administered at intermediate-hi...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2001-12, Vol.34 Suppl 4, p.S57-S59
Main Authors: Pronzato, P, Vigani, A, Tognoni, A, Vaira, F, Canessa, P
Format: Article
Language:English
Subjects:
Antibiotics, Antineoplastic - therapeutic use
Carcinoma, Non-Small-Cell Lung - drug therapy
Epirubicin - therapeutic use
Humans
Lung Neoplasms - drug therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The literature concerning the use of anthracyclines in the treatment of non-small cell lung cancer (NSCLC) is reviewed here. Overall, the activity of doxorubicin (DOXO) is unsatisfactory, whereas, the analogous epidoxorubicin (EPI) yields a 30% response rate (RR) when administered at intermediate-high doses. All active drugs, including EPI, should be considered to design the most active combination. Mainly, in the setting, in which an objective response is very important, for instance the neo-adjuvant pre-operatory setting.
ISSN:0169-5002